Agilent Technologies Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) whose tumors express PD-L1. This approval enables the identification of patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. The approval is based on results from the KEYNOTE-B96 clinical trial and marks the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx, Code SK006, for use with KEYTRUDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on February 10, 2026, and is solely responsible for the information contained therein.